These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27699717)

  • 41. BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
    Samadi P; Morissette M; Lévesque D; Di Paolo T
    Mov Disord; 2010 Jan; 25(1):116-21. PubMed ID: 20014115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Yamaguchi M; Mizuta E; Kuno S
    Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pedunculopontine nucleus electric stimulation alleviates akinesia independently of dopaminergic mechanisms.
    Jenkinson N; Nandi D; Oram R; Stein JF; Aziz TZ
    Neuroreport; 2006 Apr; 17(6):639-41. PubMed ID: 16603926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
    Koprich JB; Huot P; Fox SH; Jarvie K; Lang AE; Seeman P; Brotchie JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():151-6. PubMed ID: 23306217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic and progressive Parkinson's disease MPTP model in adult and aged mice.
    Muñoz-Manchado AB; Villadiego J; Romo-Madero S; Suárez-Luna N; Bermejo-Navas A; Rodríguez-Gómez JA; Garrido-Gil P; Labandeira-García JL; Echevarría M; López-Barneo J; Toledo-Aral JJ
    J Neurochem; 2016 Jan; 136(2):373-87. PubMed ID: 26500044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Grégoire L; Rassoulpour A; Guidetti P; Samadi P; Bédard PJ; Izzo E; Schwarcz R; Di Paolo T
    Behav Brain Res; 2008 Jan; 186(2):161-7. PubMed ID: 17868931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
    Schneider JS; Van Velson M; Menzaghi F; Lloyd GK
    Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets.
    Michel A; Nicolas JM; Rose S; Jackson M; Colman P; Briône W; Sciberras D; Muglia P; Scheller DK; Citron M; Downey P
    PLoS One; 2017; 12(8):e0182887. PubMed ID: 28854243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac sympathetic innervation in the MPTP non-human primate model of Parkinson disease.
    Carmona-Abellan M; Martínez-Valbuena I; DiCaudo C; Marcilla I; Luquin MR
    Clin Auton Res; 2019 Aug; 29(4):415-425. PubMed ID: 31338635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Ko WK; Pioli E; Li Q; McGuire S; Dufour A; Sherer TB; Bezard E; Facheris MF
    Mov Disord; 2014 May; 29(6):772-9. PubMed ID: 24610195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.